Stoke Therapeutics

STOK · NASDAQ

$26.61+$1.79 (+7.21%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.82

Latest news

Press releaseOct 16, 4:20 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseOct 12, 8:00 AM ETBusiness Wire
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Press releaseOct 6, 8:00 AM ETBusiness Wire
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Press releaseOct 5, 7:00 AM ETBusiness Wire
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Press releaseSep 23, 4:01 PM ETBusiness Wire
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Press releaseSep 16, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseSep 3, 7:30 PM ETGlobe Newswire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseSep 3, 7:30 PM ETBusiness Wire
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseSep 2, 8:00 AM ETBusiness Wire
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Press releaseSep 1, 7:30 AM ETBusiness Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseSep 1, 7:30 AM ETGlobe Newswire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Press releaseAug 18, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseAug 5, 8:00 AM ETBusiness Wire
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
NewsAug 4, 9:28 AM ETAvi Kapoor
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
Press releaseAug 3, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
Press releaseJul 27, 4:01 PM ETBusiness Wire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
Press releaseJul 16, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseJul 13, 7:30 AM ETBusiness Wire
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Press releaseJun 30, 8:00 AM ETBusiness Wire
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Press releaseJun 16, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseMay 28, 4:01 PM ETBusiness Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Press releaseMay 18, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NewsMay 7, 4:04 PM ET
Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate.
Press releaseMay 7, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Press releaseApr 30, 4:01 PM ETBusiness Wire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
Press releaseApr 16, 4:01 PM ETBusiness Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseApr 8, 4:01 PM ETBusiness Wire
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
NewsFeb 24, 8:01 AM ET
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics
NewsJan 12, 9:01 AM ET
8 Analysts Have This To Say About Stoke Therapeutics
NewsJan 12, 8:05 AM ETAvi Kapoor
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsJan 12, 4:34 AM ETAvi Kapoor
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
NewsNov 5, 6:45 AM ET
6 Analysts Have This To Say About Stoke Therapeutics
NewsNov 4, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsNov 4, 6:12 AM ET
Earnings Scheduled For November 4, 2025
NewsNov 3, 3:02 PM ET
Examining the Future: Stoke Therapeutics's Earnings Outlook
NewsOct 10, 6:01 PM ET
What 4 Analyst Ratings Have To Say About Stoke Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate.

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics

8 Analysts Have This To Say About Stoke Therapeutics

Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

6 Analysts Have This To Say About Stoke Therapeutics

12 Health Care Stocks Moving In Tuesday's After-Market Session

Earnings Scheduled For November 4, 2025

Examining the Future: Stoke Therapeutics's Earnings Outlook

What 4 Analyst Ratings Have To Say About Stoke Therapeutics